CDC Models Show Scaling Up ART for HIV Treatment Can Save Money Over Time
January 30, 2012
During a webinar Thursday hosted by the Health Global Access Project, AVAC, and amfAR (The Foundation for AIDS Research), John Blandford, chief of CDC's Division of Global HIV/AIDS Health Economics, Systems and Integration Branch, presented findings showing "that scaling up antiretroviral therapy (ART) for HIV/AIDS treatment and prevention in the developing world not only saves lives, but saves money too," the Center for Global Health Policy's "Science Speaks" blog reports. According to the blog, "[Blandford] and his team of colleagues have found that cost savings from averted negative outcomes offset a major portion of the cost of treatment over time." The blog quotes Blandford saying, "Based on [WHO] standards, ART should be considered highly cost-effective in almost every country in sub-Saharan Africa" (Mazzotta, 1/27).
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)